Coronavirus Boosts Biogen Biosimilars In First Quarter
As Company Comments On Recent US Tecfidera Ruling
Biogen reported more positive numbers for the firm’s biosimilars business in the first quarter of this year, although some of this growth was attributed to “accelerated sales” stemming from the COVID-19 pandemic. Meanwhile, the company revealed its latest thinking as it continues attempts to shield its key Tecfidera brand from competition in the US, following a fresh unfavorable patent ruling.
